52 AIM-Mar26314 Developing an innovative product is one challenge. Manufacturing it consistently under cleanroom conditions, at high volumes, and with stable quality over years of production is another. This is where Contract Development and Manufacturing Organisation (CDMO) Weidmann Medical Technology focuses its expertise: combining precision molding, automation, inline quality assurance, and scalable manufacturing into robust production systems. We heard more from Florian Lehner below, Director of Business Development, as the CDMO is named in the Healthcare and Pharmaceutical Awards 2026. “Even highly automated manufacturing processes serve a much bigger purpose: ensuring that medical products perform reliably when patient health depends on them.” Weidmann Medical Technology is a specialised CDMO for highprecision, injection-moulded components, and automated assembly solutions for the medical, pharmaceutical, and diagnostics industries. The company leverages state-of-the-art cleanroom production and expertise in complex plastic components to provide scalable, high-quality solutions. With a focus on the industrialisation of sophisticated plastic components for high-volume production, Weidmann Medical Technology’s edge lies in combining high-volume manufacturing capability, extremely tight tolerances, advanced automation, and integrated inline quality control. It also boasts strong expertise in overmoulding, insert moulding, automated assembly, inline inspection, and RFID-integrated medical components. A pure CDMO, Weidmann Medical Technology does not produce its own medical products and will therefore never compete with its customers. Conversely, it aims to serve its clients as a trusted partner for sophisticated, high-quality injection-moulding components in the medical field, ultimately contributing to better patient health. As part of the Weidmann Group, the company combines the agility of a focused medical technology CDMO with the stability and engineering culture of a globally active industrial company. One of its key strengths lies in its ability to connect development and industrialisation early in the process; through DfM and DfA, the Precision Medical Manufacturing CDMO of the Year 2026 – Switzerland team helps customers optimise products not only for functionality, but also for stable and scalable manufacturing. Furthermore, engineering, innovation, production, and project management teams work very closely together in day-to-day business at Weidmann Medical Technology. Although the company is a core part of a global industrial group, collaboration remains direct and highly efficient throughout the organisation, which plays a fundamental role in shortening feedback loops between development, production, and automation teams. “Our Swiss precision manufacturing ensures efficiency, accuracy, and scalability for demanding medical applications.” At present, the medical manufacturing industry is facing several parallel challenges: increasing regulatory and documentation requirements; shorter product life cycles and faster industrialisation timelines; geopolitical uncertainty affecting supply chains and raw material markets; and continued pressure on costs and capitalintensive production environments. Therefore, Weidmann Medical Technology has placed its focus upon projects where technical complexity and long-term partnership potential align well. These are typically long-term programmes where process capability and manufacturing reliability are businesscritical, often requiring advanced moulding expertise, automation, cleanroom manufacturing, and stable high-volume production. Over the past 12 months, Weidmann Medical Technology has further strengthened its automation and digital manufacturing capabilities, particularly for diagnostics and pharmaceutical applications. One standout milestone has been the implementation of a new highly automated product line for high-precision diagnostic consumables in Bad Ragaz. In this setup, the process runs from raw material feeding to final packaging without manual operator intervention. At the same time, the company equipped new production and inspection systems in Rapperswil and Saltillo with AI-supported monitoring capabilities. This development allows process deviations to be detected early and enables remote optimisation by Weidmann Medical Technology’s engineering teams. Weidmann Medical Technology is also currently supporting a diagnostics start-up with the industrialisation of a new product that is planned to enter clinical studies by the end of 2026. Projects like this require close collaboration between development, moulding, automation, and manufacturing from an early stage, made possible through the company’s integrated structure. “Successful collaboration in medical manufacturing is not transactional,” Florian told us. “The best results are achieved when development, industrialisation, and long-term manufacturing are approached as a shared responsibility between customer and CDMO partner.”
RkJQdWJsaXNoZXIy MTUyMDQwMA==